AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for oncology: Harnessing ubiquitin-independent pathways
University of Cambridge
Closes
Study ubiquitin-independent targeted protein degradation for oncology in Catherine Lindon’s laboratory, in partnership with AstraZeneca. The project investigates Midnolin biology and develops binding and engineered tools that redirect its activity towards therapeutic targets. The award supports four years of doctoral research.